SCHEMBL3045957

SCHEMBL3045957

O=C1COc2ccc(I)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.44
RAB9A P51151 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
PKM P14618 1/20 0.44
CYP2C19 P33261 1/20 0.44
AR P10275 1/20 0.43
MAPT P10636 5/20 0.37
KDM4E B2RXH2 2/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
TDP2 O95551 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAOB P27338 5/20 0.36
MAOA P21397 3/20 0.36
TGM2 P21980 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2227219 0.84 MAOB (0.46) HSD17B10RAB9AMEN1KMT2ANPC1
Hydrochloric Acid SCHEMBL2227227 0.82 MAOB (0.45) HSD17B10RAB9AMEN1KMT2ANPC1
SCHEMBL67612 0.81 MAOB (0.50) RAB9ANPC1SMN1; SMN2ARALDH1A1
SCHEMBL5539912 0.78 HSD17B10 (0.45) HSD17B10RAB9AMEN1KMT2ANPC1
SCHEMBL3152242 0.76 MEN1 (0.59) HSD17B10RAB9AMEN1KMT2ANPC1
SCHEMBL3223921 0.76 MAPT (0.60) HSD17B10RAB9AMEN1KMT2ANPC1
SCHEMBL1143565 0.76 APP (0.55) HSD17B10RAB9AMEN1KMT2ANPC1
SCHEMBL1429528 0.76 MAPT (0.47) HSD17B10RAB9AMEN1KMT2ANPC1
SCHEMBL95448 0.76 MMP12 (0.51) HSD17B10RAB9AMEN1KMT2ANPC1
SCHEMBL13464653 0.76 HSD17B10 (0.44) HSD17B10RAB9AMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4566612-A2 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES Recurium IP Holdings, LLC (US) 2025-06-11 EP disclosed
EP-3762385-B1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS LLC (US) 2025-02-12 EP disclosed
US-20240391924-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2024-11-28 US disclosed
CN-117720541-A Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones 里科瑞尔姆IP控股有限责任公司 2024-03-19 CN disclosed
CN-117285532-A Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones 里科瑞尔姆IP控股有限责任公司 2023-12-26 CN disclosed
CN-111902413-B Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones 里科瑞尔姆IP控股有限责任公司 2023-10-17 CN disclosed
WO-2023134656-A1 PEPTIDYL NITRILE COMPOUND AND USE THEREOF 上海壹典医药科技开发有限公司 2023-07-20 WO disclosed
US-11261192-B2 Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones RECURIUM IP HOLDINGS, LLC (US) 2022-03-01 US disclosed
US-20220024939-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2022-01-27 US disclosed
US-20210139482-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2021-05-13 US disclosed
US-20100003191-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS NAGASAKI UNIVERSITY (JP) 2010-01-07 US disclosed
US-20100003191-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS NAGASAKI UNIVERSITY (JP) 2010-01-07 US disclosed
EP-2113258-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS Nagasaki University (JP) 2009-11-04 EP disclosed
EP-2113258-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS Nagasaki University (JP) 2009-11-04 EP disclosed
US-6391902-B2 TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION SUCH AS INCONTINENCE AND IRRITABLE BOWEL SYNDROME AMERICAN HOME PRODUCTS CORPORATION 2002-05-21 US disclosed
CN-1333774-A Substituted benzofuranodindoles and indenoindoles as novel potassium channel openers AMERICAN HOME PROD (US) 2002-01-30 CN disclosed
US-20010047026-A1 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers AMERICAN HOME PRODUCTS CORPORATION 2001-11-29 US disclosed
EP-1135393-A2 SUBSTITUTED BENZOFURANOINDOLES AND INDENOINDOLES AS NOVEL POTASSIUM CHANNEL OPENERS AMERICAN HOME PRODUCTS CORPORATION (US) 2001-09-26 EP disclosed
US-6288099-B1 COMPOUNDS SUCH AS 8-BROMO-10H-BENZO(4,5)FURO(3,2-B)INDOLE-1-CARBOXYLIC ACID USED TO TREAT DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRATION SUCH AS URINARY INCONTINENCE AND IRRITABLE BOWL SYNDROME AMERICAN HOME PRODUCTS CORPORATION 2001-09-11 US disclosed
WO-2000034285-A2 SUBSTITUTED BENZOFURANOINDOLES AND INDENOINDOLES AS NOVEL POTASSIUM CHANNEL OPENERS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11261192-B2 Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones MKI67, BRCA1, CCNI HSD17B10 1017/4885RAB9A 870/4885MEN1 2466/4885
US-20010047026-A1 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers KCNJ2, KCNN3, KCNN2 HSD17B10 2898/4885RAB9A 2569/4885MEN1 2213/4885
US-20210139482-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES MKI67, BRCA1, CCNI HSD17B10 1017/4885RAB9A 870/4885MEN1 2466/4885
US-20220024939-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES MKI67, BRCA1, CCNI HSD17B10 1017/4885RAB9A 870/4885MEN1 2466/4885
US-20100003191-A1 AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS APP, APBA1, BACE1 HSD17B10 881/4885RAB9A 565/4885MEN1 508/4885
US-20240391924-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES MKI67, BRCA1, CCNI HSD17B10 1017/4885RAB9A 870/4885MEN1 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.